The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) by Seth Sandesh since 2015.
The trader's CIK number is 1566175.
At the time of the last reporting, Seth Sandesh was the Officer of Actinium Pharmaceuticals, Inc.. (stock ticker symbol ATNM).
Also see all insider trading activities at Actinium Pharmaceuticals, Inc..
Insider Buying | Insider Sales | Option Exercises | |||||
---|---|---|---|---|---|---|---|
Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
2015 | RLMD | 20,000 | $60,286 | 0 | $0 | 0 | $0 |
Insider Buying | Insider Sales | Option Exercises | |||||
---|---|---|---|---|---|---|---|
Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
2018 | ATNM | 25,000 | $14,170 | 0 | $0 | 0 | $0 |
2017 | ATNM | 45,833 | $38,136 | 0 | $0 | 0 | $0 |
2016 | ATNM | 20,000 | $34,819 | 0 | $0 | 0 | $0 |
1. Relmada Therapeutics, Inc. (RLMD)
2. Actinium Pharmaceuticals, Inc. (ATNM)
Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
---|---|---|---|---|---|
2015-12-15 | RLMD | Buy | 9,500 | 3.23 | 30,666 |
2015-12-14 | RLMD | Buy | 10,500 | 2.82 | 29,620 |
Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
---|---|---|---|---|---|
2018-12-10 | ATNM | Buy | 10,000 | .44 | 4,370 |
2018-07-17 | ATNM | Buy | 10,000 | .79 | 7,900 |
2018-04-19 | ATNM | Buy | 5,000 | .38 | 1,900 |
2017-08-02 | ATNM | Buy | 33,333 | .75 | 24,999 |
2017-06-15 | ATNM | Buy | 7,500 | 1.17 | 8,737 |
2016-12-30 | ATNM | Buy | 5,000 | .88 | 4,400 |
2016-12-12 | ATNM | Buy | 5,000 | .98 | 4,900 |
2016-04-14 | ATNM | Buy | 5,000 | 2.00 | 10,000 |
2016-04-15 | ATNM | Buy | 3,500 | 2.00 | 7,017 |
2016-04-18 | ATNM | Buy | 6,500 | 1.99 | 12,902 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Seth Sandesh (Officer of Actinium Pharmaceuticals, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.